First time available for research use

CD38-antibody

Daratumumab antibody from Darzalex®

Therapeutic CD38-antibody from the original Darzalex® commercial drug targeting the CD38-antigen, also referred to as Darzalex® or daratumumab antibody . Research-relevant quantities are available as licence-free consumable in aliquoted or diluted variant. Therapeutic monoclonal antibodies can be used from researchers in in vitro and in vivo experiments, biosimilar developers can order different batches at the same time.

Choose your antibody
cd38-antibody-daratumumab
Easy Access

Easy Access

Easy to order as license-free research consumable
Multiple batches

Multiple batches

Up to 10 batches of original drugs for examining batch-to-batch variations
Reduce costs

Reduce costs

Up to 80% less compared to the original pharmaceutical price
Prompt delivery

Prompt delivery

Shipment within days worldwide according to GDP-standards
Documented origin

Documented origin

Information on batch, registration number, expiry date, GDP-compliant pedigree

What our clients say

Daratumumab / Darzalex

Product Reference

Drug nameDarzalex®
INNDaratumumab
API typeDaratumumab is a human monoclonal IgG1κ antibody against CD38 antigen, produced in a mammalian cell line (Chinese Hamster Ovary [CHO]) using recombinant DNA technology
Pharmacotherapeutic group
Antineoplastic agents,
monoclonal antibodies
ATC code
L01XC24
Target of antibody
CD38; Synonyms: T10, Cd38-rs1, cd38, ADPRC 1, cADPr hydrolase 1
General function
Short description
Pharmacodynamic properties
(Mechanism of action; Source EMA document)
Daratumumab is an IgG1κ human monoclonal antibody (mAb) that binds to the CD38 protein expressed at a high level on the surface of multiple myeloma tumour cells, as well as other cell types and tissues at various levels. CD38 protein has multiple functions such as receptor mediated adhesion, signalling and enzymatic activity.
Daratumumab has been shown to potently inhibit the in vivo growth of CD38-expressing tumour cells. Based on in vitro studies, daratumumab may utilize multiple effector functions, resulting in immune mediated tumour cell death. These studies suggest that daratumumab can induce tumour cell lysis through complement-dependent cytotoxicity, antibody-dependent cell-mediated cytotoxicity, and antibody-dependent cellular phagocytosis in malignancies expressing CD38. A subset of myeloid derived suppressor cells (CD38+MDSCs), regulatory T cells (CD38+Tregs) and B cells (CD38+Bregs) are susceptible to daratumumab mediated cell lysis.
Daratumumab induced apoptosis in vitro after Fc mediated cross-linking. In addition, daratumumab modulated CD38 enzymatic activity, inhibiting the cyclase enzyme activity and stimulating the hydrolase activity. The significance of these in vitro effects in a clinical setting, and the implications on tumour growth, are not well-understood
Pharmacodynamic properties (Pharmacodynamic effects; Source EMA document)Natural killer (NK) cell and T-cell count
NK cells are known to express high levels of CD38 and are susceptible to daratumumab mediated cell lysis. Decreases in absolute counts and percentages of total NK cells (CD16+CD56+) and activated (CD16+CD56dim) NK cells in peripheral whole blood and bone marrow were observed with daratumumab treatment. However, baseline levels of NK cells or kinetics of NK cell decrease did not show an association with clinical response.
T cells (CD3+, CD4+, and CD8+) are also known to express CD38 depending on the stage of development and the level of activation. Significant increases in CD4+ and CD8+ T cell absolute counts, and percentages of lymphocytes, were observed with daratumumab treatment in peripheral whole blood and bone marrow. In addition, T-cell receptor DNA sequencing verified that T-cell clonality was increased with daratumumab treatment, indicating immune modulatory effects that may contribute to clinical response.
Original license holder
Marketing authorisation numbers
EU/1/16/1101/001 - 002
Marketing authorisation holder
Janssen-Cilag International NV
Turnhoutseweg 30
B-2340 Beerse
Belgium
Name of the manufacturer of the biological active substance
Biogen Inc.
5000 Davis Drive
Research Triangle Park
North Carolina
27709
United States
Janssen Biologics Ireland
Barnahely
Ringaskiddy, Co. Cork
Ireland
Name and address of the manufacturer(s) responsible for batch releaseJanssen Biologics B.V.
Einsteinweg 101
NL-2333 CB Leiden
The Netherlands
Max shelf life
18 months
Storage conditions
2°C – 8°C
List of excipients
Glacial acetic acid
Mannitol (E421)
Polysorbate 20
Sodium acetate trihydrate
Sodium chloride
Water for injections